Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, P.; Récher, C.; Vives, S.; Zarzycka, E.; Wang, Jianxiang; Bertani, Giambattista; Heuser, M.; Calado, R.; Schuh, A.; Yeh, S.; Daigle, S.; Hui, J.; Pandya, S.; Gianolio, D.; de Botton, S.; Döhner, H.

doi:10.1056/NEJMoa2117344

Public

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Shared by NobleBlocks on Apr 21, 2022 • 12:00 AM UTC

Authors:

P. Montesinos

C. Récher

S. Vives

Abstract

BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia. METHODS In this phase 3 trial, we randomly assig...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!